This is an interview with Uri Lee, CEO of Xcell Therapeutics. Xcell is an international leader in serum-free, chemically defined media. In this interview, we discuss the mission and purpose of Xcell Therapeutics, its product development pipeline, its rapid growth, and the company’s future goals. Enjoy. [Read more…]
Sponsored Content: Interivews published by BioInformant are paid content. BioInformant is not responsible for the accuracy or claims made in these interviews and does not endorse the views expressed by the interviewees.
Interview With Kaz Hirao, President & COO at Fujifilm Cellular Dynamics
Fujifilm CDI is the largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics.
The company also opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.
How CellPort Is Making Cell Culture Smarter – Interview with Patrick Dentinger, CEO of CellPort Software
In the dynamic world of cell therapy, where precision and reproducibility are paramount, one scientist’s frustration with cell unpredictability sparked an industry-changing innovation. After years at the bench wrestling with the inherent variability of cell culture, Patrick Dentinger recognized a deeper problem—labs weren’t equipped with the right tools to track, understand, and manage cellular drift. [Read more…]
Cord Blood Banking in Latin America – Interview with James Mendez of Cryoholdco
In this interview with James Alexis Mendez, we discuss the market strategy of CryoHoldco, a stem cell bank holding company that is the market leader in Latin America and one of the ten largest cord blood banks in the world. James Alexis Mendez currently serves as the CFO and Board member of CryoHoldco. Approaching 200,000 stem cell units in storage, CryoHoldco is more than 5X larger than any other stem cell bank in Latin America. CryoHoldco owns the cord blood market leaders in both Mexico and Colombia, and plans to expand into other regions of Latin America. [Read more…]
Amniotic Stem Cells: An Extension of the Cord Blood Banking Model
Amniotic stem cells, which can be sourced from the amniotic fluid or the placenta after a live, healthy birth, possess a unique blend of multipotency and lack of tumorigenicity. In an extension of the cord blood banking model, these cells may improve outcomes where long-term cell survival and functionality is important. Recently, I had the honor of interview Dr. Todd McAllister, Executive Director at the Amnion Foundation, a non-profit organization with the mission to build a genetically diverse public cell bank that can provide an immunological match to the majority of the population.
In this interview, we discuss the Amnion Foundation’s vision, research and clinical approach, scale-out strategy, and interest in joint partnerships that will support greater utilization of amniotic stem cells. It is captivating to get an insider look at the Amnion Foundation, a non-profit that is introducing a new extension to the traditional cord blood and tissue banking market.
As the cord blood banking market matures and consolidates and diversifies into new types of perinatal stem cell storage, the Amnion Foundation will be uniquely positioned to advise cord blood banks on how to integrate amniotic stem cell banking into their service portfolio.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 15
- Next Page »